<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04283318</url>
  </required_header>
  <id_info>
    <org_study_id>HS-2018-01</org_study_id>
    <nct_id>NCT04283318</nct_id>
  </id_info>
  <brief_title>Prolonged Fasting on Glucose Metabolism and Hormonal Regulation in Healthy, Obese and Subjects With Type 2 Diabetes</brief_title>
  <acronym>PROLOG</acronym>
  <official_title>The Effects of Prolonged Fasting on Glucose Metabolism and Hormonal Regulation in Healthy, Obese and Subjects With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Graz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Graz</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In a previous study investigating the effects of intermittent fasting, our research group
      found evidence for higher glucose excursions and a reduced insulin response after a 36 hour
      fasting period as compared to an overnight fasting period in healthy subjects.

      The aim of this research project is to investigate the effect of short and midterm fasting
      (12 hours versus 36 hours) on glucose metabolism, glucose regulatory hormones, insulin
      secretion and resting energy expenditure in healthy and obese people as well as in patients
      with type 2 diabetes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this clinical study, we want to examine the effects of different fasting periods (12 hours
      versus 36 hours) on blood sugar levels and other metabolic parameters and hormones. For this
      the following investigations are carried out:

        -  Oral glucose tolerance test with detailed laboratory evaluation

        -  Bio-impedance measurement to determine body composition (muscle and fat mass)

      The examinations are carried out on 4 different cohorts (normal healthy persons, obese
      patients, patients with type 2 diabetes and patients with type 1 diabetes).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 13, 2018</start_date>
  <completion_date type="Anticipated">December 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change of 2h glucose levels</measure>
    <time_frame>after 12 and 36 hours of fasting</time_frame>
    <description>Difference in the change of 2h glucose levels in an oral glucose tolerance test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>changes in insulin sensitivity (QUICKI)</measure>
    <time_frame>after 12 and 36 hours of fasting</time_frame>
    <description>differences in QUICKI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in insulin sensitivity (Matsuda Index)</measure>
    <time_frame>after 12 and 36 hours of fasting</time_frame>
    <description>differences in Matsuda Index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in insulin sensitivity (ISI)</measure>
    <time_frame>after 12 and 36 hours of fasting</time_frame>
    <description>differences in ISI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in insulin sensitivity (HOMA-Index)</measure>
    <time_frame>after 12 and 36 hours of fasting</time_frame>
    <description>differences in HOMA-Index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in glycaemic pattern</measure>
    <time_frame>after 12 and 36 hours of fasting</time_frame>
    <description>differences in area under the curve (AUC) of glycaemic pattern in Oral glucose tolerance test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in body composition</measure>
    <time_frame>after 12 and 36 hours of fasting</time_frame>
    <description>differences in bioimpedance analysis</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Healthy</condition>
  <condition>Obesity</condition>
  <condition>Type 2 Diabetes Mellitus</condition>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>Healthy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Age &gt;18 years; BMI 20-27 kg/m2; Fasting plasma Glucose &lt;110 mg/dL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Obese people</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Age &gt;18 years; BMI &gt;30 kg/m2; Fasting Plasma Glucose &lt;110 mg/dL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Type 2 Diabetes</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Age &gt;18 years; Diagnosed Type 2 Diabetes mellitus (diet or a monotherapy or combination of metformin, DPP-4-inhibitors or sulfonylurea)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Type 1 Diabetes</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Age &gt;18 years; Diagnosed Type 1 Diabetes mellitus &gt;12 months; Treated with multiple daily Insulin injections (MDII) or continuous subcutaneous Insulin Infusion (CSII); Stable Insulin therapy as clinically assessed by the study physician C-Peptide negative defined as 0.3 nmol/L; No diabetic ketoacidosis within the last 12 months; No severe hypoglycaemia requiring external assistance within the last 12 months; Running on the FreeStyle Libre 1 (Abbott, USA) intermittently-viewed continuous Glucose Monitoring System (iCGM) as Standard of care for Glucose monitoring</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>12h fasting</intervention_name>
    <description>12h fasting (overnight)</description>
    <arm_group_label>Healthy</arm_group_label>
    <arm_group_label>Obese people</arm_group_label>
    <arm_group_label>Type 1 Diabetes</arm_group_label>
    <arm_group_label>Type 2 Diabetes</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>36h fasting</intervention_name>
    <description>36h fasting ( one day and two nights fasting)</description>
    <arm_group_label>Healthy</arm_group_label>
    <arm_group_label>Obese people</arm_group_label>
    <arm_group_label>Type 1 Diabetes</arm_group_label>
    <arm_group_label>Type 2 Diabetes</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Gender: Both, male and female Minimum Age: 18 years

        Inclusion Criteria Cohort I (Healthy, non-obese subjects) Age &gt;18 years; body mass index in
        the range of 20.0-27.0 kg/m2; fasting plasma glucose &lt;110mg/dL

        Inclusion criteria cohort II (Obese subjects) Age &gt;18 years; body mass index &gt;30 kg/m2;
        fasting plasma glucose &lt;110mg/dL

        Inclusion Criteria Cohort III (Cohort with subjects with Type 2 Diabetes Mellitus) Age &gt;18
        years; established Diabetes mellitus type 2 on either diet or a monotherapy or combination
        of metformin, Dipeptidylpeptidase (DPP)-4-inhibitors or sulfonylurea

        Inclusion Criteria Cohort IV (Cohort with subjects with Type 1 Diabetes Mellitus) Age &gt;18
        years; diagnosed with Type 1 Diabetes Mellitus &gt;12 months; treated with multiple daily
        Insulin injectioins (MDII) or continuous subcutaneous Insulin Infusion (CSII); stable
        Insulin therapy as clinically assessed by the study physician; C-Peptide negative defined
        as 0.3 nmol/L; HbA1c &lt;9.5%; no diabetic ketoacidosis within the last 12 months; no severe
        hypoglycaemia requiring external assistance within the last 12 months; running on the
        FreeStyle Libre 1 (Abbott, USA) intermittently-viewed continuous Glucose Monitoring System
        (iCGM) as Standard of care for Glucose monitoring

        Exclusion Criteria (for all participants) History of cardiovascular disease; acute or
        chronic inflammatory disorder; heavy drinking (more than 15 drinks/week); dietary
        restrictions (e.g. vegetarianism and vegan); insulin Treatment (excluded subjects with Type
        1 Diabetes Mellitus); corticosteroid therapy; known malignancy; women who are pregnant,
        breast-feeding or trying to become pregnant; history of any chronic disease process that
        could interfere with interpretation of study results; therapy with antidepressants within
        past 6 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Harald Sourij, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Graz, Auenbruggerplatz 15</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Norbert Tripolt, PhD</last_name>
    <phone>+43316385</phone>
    <phone_ext>78038</phone_ext>
    <email>norbert.tripolt@medunigraz.at</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Harald Sourij, MD</last_name>
    <phone>+4331638581310</phone>
    <phone_ext>81310</phone_ext>
    <email>ha.sourij@medunigraz.at</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical University of Graz</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Norbert Tripolt, PhD</last_name>
      <phone>31638578038</phone>
      <email>norbert.tripolt@medunigraz.at</email>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>February 18, 2019</study_first_submitted>
  <study_first_submitted_qc>February 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 25, 2020</study_first_posted>
  <last_update_submitted>May 14, 2020</last_update_submitted>
  <last_update_submitted_qc>May 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>starvation</keyword>
  <keyword>healthy people</keyword>
  <keyword>obese</keyword>
  <keyword>Type 2 diabetes mellitus</keyword>
  <keyword>glucose metabolism</keyword>
  <keyword>Type 1 diabetes mellitus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

